A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder

Neuropsychiatric Disease and Treatment

Volumn 9, Issue 1, 2012, Pages 101-111

  Tränkner, Anja ^a   Sander, Christian ^a   Schönknecht, Peter ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Bipolar depression; Bipolar disorder; Lamotrigine

Indexed keywords

CITALOPRAM; FLUOXETINE PLUS OLANZAPINE; GABAPENTIN; INOSITOL; LAMOTRIGINE; LITHIUM; PAROXETINE; PLACEBO; RISPERIDONE; TRANYLCYPROMINE;

ADJUVANT THERAPY; ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CLINICAL GLOBAL IMPRESSION SCALE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERANCE; HAMILTON SCALE; HUMAN; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW;

EID: 84872858248     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S37126     Document Type: Review

References (65)

1. Merikangas KR, Jin R, He JP, etal. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-251.
2. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs. 1995;50(4):691-713.
3. Li X, Ketter TA, Frye MA. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord. 2002;69(1-3)1-14.
4. Prica C, Hascoet M, Bourin M. Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression. Behav Brain Res. 2008;191(1):49-54.
5. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003;63(19):2029-2050.
6. Seo HJ, Chiesa A, Lee SJ, etal. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol. 2011;34(1):39-47.
7. ®(lamotrigine) tablets, chewable dispersible tablets, orally disintegrating tablets [prescribing information]. North Carolina: GlaxoSmithKline; Dec 2011; Revised 09/2012. Available from: http://us.gsk.com/products/assets/us_lamictal.pdf. Accessed November 24, 2012.
8. Goodwin GM; for Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346-388.
9. Yatham LN, Kennedy SH, Schaffer A, etal. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225-255.
10. National Institute for Health and Clinical Excellence. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. NICE Clinical Guideline 38. London: National Institute for Health and Clinical Excellence; 2006 [updated March 30, 2010]. Available from: http://www.nice.org.uk/nicemedia/live/10990/30193/30193.pdf. Accessed September 10, 2012.
11. Grunze H, Kasper S, Goodwin G, etal; World Federation of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry. 2002;3(3):115-124.
12. Grunze H, Kasper S, Goodwin G, etal; WFSBP Task force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry. 2003;4(1):5-13.
13. Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry. 2004;5(3):120-135.
14. Grunze H, Vieta E, Goodwin GM, etal; WFSBP Task Force On Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81-109.
15. Grunze H, Vieta E, Goodwin GM, etal. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85-116.
16. Mok YM, Chan HN, Chee KS, etal; Ministry of Health. Ministry of Health clinical practice guidelines: bipolar disorder. Singapore Med J. 2011;52(12):914-918; quiz 919.
17. Pfennig A, Bschor T, Baghai T, etal. S3guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations. Nervenarzt. 2012;83(5):568-586. German.
18. Amann B, Born C, Crespo JM, Pomarol-Clotet E, McKenna P. Lamotrigine: when and where does it act in affective disorders? A systematic review. J Psychopharmacol. 2011;25(10):1289-1294.
19. Cipriani A, Barbui C, Salanti G, etal. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306-1315.
20. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36(2):375-389.
21. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60(2):79-88.
22. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry. 2009;194(1):4-9.
23. Calabrese JR, Huffman RF, White RL, etal. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008;10(2):323-333.
24. Frye MA, Ketter TA, Kimbrell TA, etal. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607-614.
25. Brown EB, McElroy SL, Keck PE Jr, etal. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67(7):1025-1033.
26. Brown E, Dunner DL, McElroy SL, etal. Olanzapine/fluoxetine combination vs lamotrigine in the 6-months treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009;12(6):773-782.
27. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord. 2006;96(1-2):95-99.
28. Nolen WA, Kupka RW, Hellemann G, etal. Tranylcypromine vs lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007;115(5):360-365.
29. Bowden CL, Calabrese JR, Sachs G, etal; Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400.
30. Calabrese JR, Bowden CL, Sachs G, etal; Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013-1024.
31. Goodwin GM, Bowden CL, Calabrese JR, etal. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65(3):432-441.
32. van der Loos ML, Mulder PG, Hartong EG, etal. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-231.
33. van der Loos ML, Mulder P, Hartong EG, etal; for LamLit Study Group. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord. 2011;13(1):111-117.
34. Chang JS, Moon E, Cha B, Ha K. Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7): 1322-1326.
35. Nierenberg AA, Ostacher MJ, Calabrese JR, etal. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163(2):210-216.
36. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry. 2000;12(1):5-10.
37. Calabrese JR, Suppes T, Bowden CL, etal. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 2000;61(11):841-850.
38. Bowden CL, Calabrese JR, McElroy SL, etal. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry. 1999;45(8):953-958.
39. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011;72(3): 356-366.
40. Vieta E, Carné X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom. 2005;74(1):10-16.
41. Ketter TA, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial. J Clin Psychiatry. 2006;67(3):400-406.
42. Goldberg JF, Calabrese JF, Saville BR, etal. Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. J Clin Psychiatry. 2009;79(9):1273-1280.
43. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord. 2010;12(5):483-493.
44. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord. 2007;9(6):551-560.
45. Fatemi SH, Rapport DJ, Calabrese JR, Thuras P. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 1997;58(12):522-527.
46. Hurley SC. Lamotrigine update and its use in mood disorders. Ann Pharmacother. 2002;36(5):860-873.
47. Kusumakar V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder. Am J Psychiatry. 1997;154(8):1171-1172.
48. Walden J, Hesslinger B, van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry. 1996;29(5):193-195.
49. Walden J, Schaerer L, Schloesser S, Grunze H. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Disord. 2000;2(4):336-339.
50. Walden J, Grunze H. Prospective, randomized study on valproate, lithium, valproate+ lithium and lamotrigine in Bipolar I rapid cycling patients. Proceedings of the SMRI Research Center conference; November 8, 2002; Bethesda, MD.
51. Maina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry. 2008;69(4):609-616.
52. Sharma V, Khan M, Corpse C. Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review. J Affect Disord. 2008;111(1):100-105.
53. Suppes T, Marangell LB, Bernstein IH, etal. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord. 2008;111(2-3):334-343.
54. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163(7): 1199-1201.
55. Dossett EC, Land AJ, Gitlin MJ, Frye MA. Lack of mania prophylaxis associated with lamotrigine monotherapy in manic-predominant bipolar I disorder. J Clin Psychiatry. 2007;68(6):973-974.
56. Ghaemi SN, Schrauwen E, Klugman J, etal. Long-term lamotrigine plus lithium for bipolar disorder: One year outcome. J Psychiatr Pract. 2006;12(5):300-305.
57. Mokhber N, Lane CJ, Azarpazhooh MR, etal. Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran. Neuropsychiatr Dis Treat. 2008;4(1):227-234.
58. Nierenberg AA. Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine. Evid Based Ment Health. 2007;10(1):12.
59. Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006;8(3):289-293.
60. Schieber FC, Boulton DW, Balch AH, etal. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Hum Psychopharmacol. 2009;24(2):145-152.
61. Spaulding T, Westlund R, Thomason C, White R, Dann R, Thompson T. Adjunctive treatment for mood stabilization of patients with bipolar I disorder treated with lamotrigine. CNS Spectr. 2006;11(9):711-716; quiz 719.
62. Calabrese JR, Rapport DJ, Youngstrom EA, Jackson K, Bilai S, Findling RL. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur Psychiatry. 2005;20(2):92-95.
63. Jadad AR, Moore RA, Carroll D, etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
64. Calabrese JR, Bowden CL, McElroy SL, etal. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry. 1999;156(7):1019-1023.
65. Obrocea GV, Dunn RM, Frye MA, etal. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51(3):253-260.